(Sharecast News) - Swiss pharmaceutical firm Novartis said on Tuesday that it has agreed to buy US clinical-stage biopharmaceutical company Tourmaline Bio for $1.4bn.
Tourmaline is focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease.

Novartis said that pacibekitug complements its cardiovascular strategy by...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE